NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.00 Consensus Price Target from Brokerages

Shares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have earned a consensus rating of "Buy" from the five analysts that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock in the last year is $43.00.

NAMS has been the subject of several recent research reports. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a research report on Monday, March 3rd. Wall Street Zen cut NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Needham & Company LLC reduced their price target on NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, Scotiabank raised their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th.

NewAmsterdam Pharma Trading Down 3.4%

Shares of NAMS stock traded down $0.60 during trading hours on Friday, hitting $17.01. 807,213 shares of the company were exchanged, compared to its average volume of 866,757. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $27.29. The business has a 50 day moving average of $18.46 and a two-hundred day moving average of $21.18. The company has a market capitalization of $1.87 billion, a PE ratio of -9.05 and a beta of 0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The company had revenue of $2.98 million for the quarter, compared to analysts' expectations of $1.46 million. On average, research analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Activity at NewAmsterdam Pharma

In related news, Director James N. Topper acquired 4,005 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were bought at an average price of $21.02 per share, for a total transaction of $84,185.10. Following the purchase, the director now directly owns 3,012,434 shares in the company, valued at approximately $63,321,362.68. This trade represents a 0.13% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at approximately $305,550. The trade was a 90.91% decrease in their position. The disclosure for this sale can be found here. Insiders own 20.84% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NAMS. Quarry LP bought a new stake in shares of NewAmsterdam Pharma in the 1st quarter valued at about $25,000. GF Fund Management CO. LTD. bought a new position in NewAmsterdam Pharma during the fourth quarter worth $50,000. National Bank of Canada FI acquired a new position in NewAmsterdam Pharma in the 4th quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $80,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of NewAmsterdam Pharma by 130.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after buying an additional 3,390 shares in the last quarter. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.